Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Alcon, Alnylam, Merck, and More


Title: Methods for Detection and Quantitation of Small RNAs

Patent Number: 8,399,221

Filed: Nov. 4, 2008

Lead Inventor: Daniel Kim, SA Biosciences

The invention, the patent’s abstract states, relates to “improved methods that increase the specificity and sensitivity of detection of small RNAs, including miRNAs, using oligonucleotide primers and nucleic acid amplification. … Reaction conditions that result in preferential decrease in cDNA synthesis of RNAs other than the small RNA molecules targeted for detection during miRNA tailing and reverse transcription reactions are described. Using these reaction conditions greater sensitivity and specificity of amplification of small RNAs including miRNAs is achieved.”

Title: Compositions and Methods for Detecting Small RNAs and Uses Thereof

Patent Number: 8,399,222

Filed: Nov. 25, 2009

Lead Inventor: Amara Siva, Gen-Probe

The patent, its abstract states, claims “compositions and methods … for the detection of small RNA target nucleic acids, preferably miRNA target nucleic acids. … The compositions and methods include using one or more … amplification oligomer that is preferably an extender primer, a target capture oligomer that is preferably at least partially double stranded, a promoter primer/provider, a reverse primer that is preferably a universal primer, and a detection probe. The compositions and methods are useful for diagnostics, prognostics, monitoring the effectiveness of treatment, and/or determining a treatment.”

Title: Methods of Using miR-34 as a Biomarker for TP53 Functional Status

Patent Number: 8,399,248

Filed: Dec. 14, 2010

Lead Inventor: Michele Cleary, Merck

The invention, the patent’s abstract states, “generally relates to use of miR-34 as a biomarker to estimate TP53 function in a cell. In another aspect, the invention generally relates to multiple uses of miR-34 and siRNAs functionally and structurally related to miR-34 for the treatment of cancer.”

Title: Compositions for Transfection of Oligonucleotides Active for Gene Silencing and Their Biological and Therapeutical Applications

Patent Number: 8,399,422

Filed: April 5, 2007

Lead Inventor: Patrick Neuberg, Polyplus Transfection

The invention, the patent’s abstract states, relates to compositions of transfection comprising an oligonucleotide and an amphiphilic cationic molecule. … The invention [further] relates to compositions active for oligonucleotide delivery into eukaryotic cells in culture, ex vivo or in vivo … [as well as] compositions of transfection comprising an oligonucleotide active for RNA interference. Such compositions can be used as tools for biological studies or as drugs for therapies.”

Title: Method for Treating Breast Cancer Using Adenine Nucleotide Translocator 2 siRNA or ANT2 shRNA

Patent Number: 8,399,426

Filed: Feb. 18, 2011

Lead Inventor: Chul Woo Kim, Bioinfra

The invention relates to “adenine nucleotide translocator 2 siRNA or … shRNA suppressing the expression of ANT2 gene expression and [an] anti-cancer agent containing the same,” according to the patent’s abstract. “Furthermore, the … invention relates to methods for treating breast cancers or stem cells of a breast cancer by treating the same with ANT2 siRNA or ANT2 shRNA. In addition, the invention provides a method for inhibiting metastasis of breast cancer cells with ANT2 siRNA or ANT2 shRNA.”

Title: Reagents, Methods, and Systems to Suppress Pro-Inflammatory Cytokines

Patent Number: 8,399,427

Filed: Feb. 9, 2012

Inventor: Jeffrey Marx, Warsaw Orthopedic

The invention relates to “reagents, methods, and systems to treat inflammation and pain in a subject using small interfering RNA molecules targeted to either TNF-alpha, IL1, IL6, and other pro-inflammatory cytokines,” the patent’s abstract states.

Title: Transferrin/Transferrin Receptor-Mediated siRNA Delivery

Patent Number: 8,399,653

Filed: May 20, 2011

Lead Inventor: Jon Chatterton, Alcon

The invention, the patent’s abstract states, “provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor. Therapeutic uses for the conjugates are also provided.”

Title: siRNA Targeting Catenin, Beta-1

Patent Number: 8,399,654

Filed: May 8, 2012

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CTNNB1.”

Title: Methods and Compositions for the Detection and Treatment of Cancer Involving miRNAs and miRNA Inhibitors and Targets

Application Number: 20130064810

Filed: Feb. 28, 2011

Lead Inventor: Hans-Guido Wendel, Memorial Sloan-Kettering Cancer Center

The invention, the patent application’s abstract states, “relates to microRNAs [that] are associated with cancer … including hematologic malignancies and particularly T-cell acute lymphoblastic leukemia, and to the assessment and modulation thereof in the treatment and management of cancer. The … invention is directed to methods and compositions for diagnosing and treating cancer, particularly T-ALL, by modulating miRNAs, and the use of miRNAs and antagonists … for predicting and assessing response to treatment, in assays for isolating and selecting antagonists, and as compositions for the treatment and management of cancer. Methods and compositions are provided for treatment or alleviation of cancer, particularly T-ALL, with antagonists/antagomirs of miRNAs, particularly one or more of miR-19b, miR-20a, miR26, miR92, miR148, and miR223.”

Title: Compositions and Methods for Inhibiting Viral Replication

Application Number: 20130064879

Filed: Aug. 24, 2012

Lead Inventor: Matthias John, Alnylam Pharmaceuticals

The invention relates to a “double-stranded ribonucleic acid having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3'-untranslated region of a [plus] strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier,” according to the patent application’s abstract. “The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the [plus] strand RNA virus, as well as methods for inhibiting viral replication.”

Title: Novel Cationic Lipids and Methods of Use Thereof

Application Number: 20130064894

Filed: Aug. 30, 2012

Lead Inventor: Alan Martin, Protiva Biotherapeutics (Tekmira Pharmaceuticals)

The invention comprises “compositions and methods for the delivery of therapeutic agents to cells,” the patent application’s abstract states. “In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knockdown of a specific target protein at relatively low doses. In addition, the compositions and methods of the … invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.”

Title: Compositions and Methods for Treating Prostate Cancer

Application Number: 20130064881

Filed: Sept. 7, 2012

Lead Inventor: John Nemunaitis, Gradalis

The invention comprises “compositions and methods to interfere with androgen receptor action based on bifunctional shRNA, targeting the AR, and/or expression of [coactivator]-derived peptides,” according to the patent application’s abstract.

Title: siRNA-Mediated Gene Silencing

Application Number: 20130065298

Filed: Nov. 5, 2012

Lead Inventor: Beverly Davidson, University of Iowa

The invention is “directed to small interfering RNA molecules targeted against an allele of interest, and methods of using these siRNA molecules,” the patent application’s abstract states.

Title: Use of RNA Interference for the Creation of Lineage-Specific ES and Other Undifferentiated Cells and Production of Differentiated Cells In Vitro by Co-Culture

Application Number: 20130065307

Filed: April 16, 2012

Inventor: Joe Cibelli, Advanced Cell Technology

The invention comprises “methods for making human ES cells and human differentiated cells and tissues for transplantation ... whereby the cells and tissues are created following somatic cell nuclear transfer. The nuclear transfer donor is genetically modified prior to nuclear transfer such that cells of at least one developmental lineage are de-differentiated … thereby resolving the ethical dilemmas involved in reprogramming somatic cells back to the embryonic stage. The method concomitantly directs differentiation such that the desired cells and tissues may be more readily isolated.”

Title: Mutator Activity Induced by microRNA-155 Links Inflammation and Cancer

Application Number: 20130065938

Filed: March 7, 2012

Inventor: Carlo Croce, Ohio State University

The patent application, its abstract states, claims “methods of reducing spontaneous mutation rate of a cell in a subject in need thereof by reducing endogenous levels of miR-155.”

Title: Compositions and Methods for Silencing Genes Expressed in Cancer

Application Number: 20130065939

Filed: Sept. 23, 2010

Lead Inventor: Adam Judge, Protiva Biotherapeutics (Tekmira Pharmaceuticals)

The invention, the patent application’s abstract states, “provides therapeutic nucleic acids such as interfering RNA that target the expression of genes associated with tumorigenesis and/or cell transformation, lipid particles comprising one or more of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles.”

Title: Double-Stranded RNA Molecules with Stability in Mammalian Body Fluid, Preparation and Application Thereof

Application Number: 20130065940

Filed: Oct. 2, 2012

Lead Inventor: Quan Du, Peking University

The invention relates to the “preparation and application of double-stranded RNA molecules stable in mammalian body fluids,” the patent application’s abstract states. “The mammalian body fluid-stable RNA molecules disclosed in the … invention are comprised of only unmodified nucleotides. For the first time, the … invention discloses the applications of mammalian-body-fluid-stable RNA molecules for immunotherapy and siRNA drug development.”

Title: Compositions and Methods for Inhibiting Expression of CD45 Gene

Application Number: 20130065943

Filed: Sept. 12, 2012

Lead Inventor: Antonin De Fougerolles, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the CD45 gene,” the patent application’s abstract states.

Title: Materials and Methods Related to Modulation of Mismatch Repair and Genomic Stability of miR-155

Application Number: 20130065946

Filed: March 22, 2011

Lead Inventor: Carlo Croce, Ohio State University

The invention provides “materials and methods related to modulation of mismatch and genomic stability by miR-155,” the patent application’s abstract states.

Title: microRNA miR-31 as a Therapeutic Approach for the Treatment of Cancer

Application Number: 20130065949

Filed: Oct. 14, 2010

Lead Inventor: Martin Matzuk, Baylor College of Medicine

The invention, the patent application’s abstract states, “generally concerns methods and compositions for treating and/or preventing cancer with microRNAs. In specific embodiments, the … invention encompasses a particular microRNA, microRNA-31, as useful in cancer therapy and/or prevention. Specific cancers may be treated, including at least ovarian, prostate, urothelial, osteosarcoma, and glioblastoma.”